Drug Device Combination Products Market

Drug Device Combination Products Market (Services) by Type of Device, Service Focus Area, Company Size and Key Geographical Regions (North America, Europe, Asia, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    133

  • Pages
    212

  • View Count
    10486

Drug Device Combination Products Market

The drug device combination products market (services) is estimated to be worth $252 million in 2022 and is expected to grow at compounded annual growth rate (CAGR) of 10% during the forecast period. Non-adherence to prescribed medication regimen is one of the major factors that not only causes negative implications on the patient’s health, but also adds to the overall pharmaceutical industry’s burden. According to an article published by Contract Pharma in April 2022, non-adherence to prescribed medicines is estimated to cost more than USD 250 billion annually to the drug developers. Further, lack of effective methods / solutions for sustained / controlled release of active pharmaceutical ingredient (API) at the targeted delivery sites is another challenge in efficient drug delivery. Notably, inadequate methods to control the release of API into the body cause fluctuations in plasma levels, leading to various side effects.

Among other approaches used for efficient drug delivery, the introduction of combination products has garnered the attention of many developers within the pharmaceutical industry. Combination products comprise of two or more FDA- regulated components that provide controlled release of the APIs. However, the development of drug-device combination products is a long-drawn-out process that not only requires novel technologies and processes but also a huge amount of capital and expertise. In addition, drug-device compatibility, user needs, release testing / testing methods, production, and packaging requirements are other factors that add to complexity in commercialization of combination products. In order to overcoming these challenges and enhance patient experience, several combination product developers are outsourcing their operations to companies that offer services for testing and validating the efficacy of their combination products.

Presently, there are several combination product service providers which claim to employ various strategic approaches to support product development and testing to provide safe, effective combination products that meet user needs. These players provide the most suitable characterization methods that help manufacturers throughout the development and manufacturing process. Some of the common features provided by the combination product service providers include providing access to GMP-certified facilities, larger capacities, new technologies, and greater operational flexibility. Further, in order to address the existing challenges in combination product development and manufacturing, service providers are actively expanding their current geographical reach and broadening their respective services portfolio. With rising need for effective drug delivery in terms of controlled drug release and the increased focus of service providers towards the development and commercial manufacturing of combination products, the drug device combination products market is likely to witness a significant market growth during the forecast period.

This image highlights the context of Combination Product Services Market report. A growing interest towards combination products, coupled with the ongoing challenges of combining drug / biologic with a medical device, is anticipated to drive the demand for outsourcing drug-device combination product development and testing This image provides list of Combination Product Service Providers. At present, more than 25 companies across the globe offer services for the development and testing of various drug-device combination products This image presents current market landscape of Combination Product Services Providers. Service providers claim to have the necessary expertise to provide a wide range of services for different types of combination products; majority of these services are focused on product development

Key Service Providers in Drug Device Combination Products Market

Examples of key service providers engaged in drug device combination products market (which have also been profiled in this market report; the complete list of companies is available in the full report) include EKG LABS, Eurofins Medical Device Testing, Exponent, Kymanox, Medical Engineering Technologies, Pace Analytical Services, Suttons Creek and West Pharmaceutical Services. This market report includes an easily searchable excel database of all the companies providing drug device combination product services, worldwide.

Recent Developments in Drug Device Combination Products Market

Several recent developments have taken place in the field of drug device combination products market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In March 2024, SHL entered into a collaboration with Swiss CDMO ten23 with the aim to provide services to companies requiring sterile drug / device combination products by combining the ten23's contract development and manufacturing organization capabilities with SHL Medical's autoinjector device technology.
  • In December 2023, Hovione, a specialist integrated CDMO in spray drying and particle engineering, has expanded its nasal drug delivery capabilities with the addition of a family of nasal powder delivery devices developed in partnership with IDC.
  • In September 2023, the European Union proposed legislative to reform rules for drug-device combinations, product information and pharmacovigilance. The reform aimed to ensure that patients across the EU have access to medicines, there is security of supply, the regulatory pharmaceutical framework is simplified and adapted to scientific, technological and environmental changes.
  • In June 2023, Endo launched PREVDUO™ first and the only FDA approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe with an aim to increase efficiency for hospitals and healthcare providers. 
  • In May 2023, MoonLake Immunotherapeutic entered into a collaboration with SHL Medical, with an aim to develop an autoinjector for clinical and commercial supply of MoonLake’s Nanobody® sonelokimab which is used for the treatment of patients suffering from dermatologic and rheumatic inflammatory indications. 
  • In May 2023, Innoviva Specialty Therapeutics announced the FDA approval of XACDURO® used for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia for intravenous use in patients 18 years of age and older. 

Scope of the Report

The “Drug Device Combination Products Market (Focus on Particle Testing, Performance Testing and Product Development)  by Type of Device (Autoinjectors, Prefilled Syringes, Large Volume Wearable Injectors and Other Types of Devices) Service Focus Area (Particle Testing, Performance Testing and Product Development), Company Size (Very Small, Small, Mid-sized, Large and Very Large Companies), and Key Geographical Regions (North America, Europe, Asia, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” market report features an extensive study of current market landscape, market size, market share, market forecast, market outlook and future opportunities for drug device combination products market. The market research report features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in drug device combination products market. Amongst other elements, the market report features:

  • A detailed assessment of the market landscape of combination product service providers based on several relevant parameters, such as year of establishment, company size (very small, small, mid-sized, large and very large), location of headquarters, type of combination product(s) (drug delivery device / system, device coated / impregnated with drug, and  other types of combination products), type of device(s) (autoinjectors, pen-injectors, prefilled syringes, large volume wearable injectors and other types of devices), service focus area(s) (particle testing, performance testing, and product development), type of service(s) offered (chemical characterization / testing, closure integrity testing, packaging validation, process development and validation, stability studies and other types of services), location of facility and leading players (in terms of number of services offered). 
  • A detailed company competitiveness analysis of combination product service providers, based on supplier power (based on the experience of the developer in this industry) and service portfolio strength based on several relevant parameters, such as type of combination product(s) (device coated / impregnated with drug, drug delivery device / system, and other types of combination products), type of device(s) (autoinjectors, pen-injectors, prefilled syringes, large volume wearable injectors and other types of devices), service focus area(s), (particle testing, performance testing, and product development), types of service(s) offered (chemical characterization / testing, closure integrity testing, packaging validation, process development and validation, stability studies and other types of services), and number of accreditations / certifications.
  • Elaborate profiles of key players that offer services for development and testing of combination products. Each profile features a brief overview of the company, along with information on year of establishment, location of headquarters, number of employees, key executives, recent developments and an informed future outlook.
  • A detailed analysis of the recent expansions undertaken by various combination product service providers, based on several relevant parameters, such as year of expansion, type of expansion (capacity expansions, facility expansions and new facility addition), location of expanded facility, most active players (in terms of number of recent expansions) and geographical distribution.
  • A case study on most advanced and popular combination products, including large volume wearable injectors and prefilled syringes combination products, providing information on their developer(s) and combination product specific features. Details of specific parameters captured for different product categories are mentioned as follows:
  • Large Volume Wearable Injector Combination Products: These products have been analyzed based on phase of development, type of device, drug compatibility, type of dosage, route of administration, method of administration, therapeutic area, storage volume / capacity, usability, technology used, mechanism of action and type of drug container.
  • Prefilled Syringe Combination Products: These therapies that have been approved / are being developed in combination with prefilled syringes have been analyzed based on type of drug molecule,  year of approval (for approved therapies), geography (for approved therapies), route of administration, therapeutic area, dose strength (for approved therapies), and other available dosage forms (for approved therapies).
  • A list of more than 90 combination product developers that are likely to partner with combination product service providers (with regard to likely collaboration opportunities for combination product development and testing). These players have been shortlisted based on various parameters, such as pipeline strength, developer strength and product strength.
  • An insightful outsourcing: go or no go framework analysis, highlighting the various factors that need to be taken into consideration by combination product developers while deciding whether to develop their respective products in-house or engage the services of a service provider. Further, the analysis highlights all the key parameters that must be considered by players based on company sizes (very small, small, mid-sized, and large), while taking the aforementioned decision.
This image highlights competitve analysis of players engaged in the domain of Combination Product Services. In order to gain an edge in this competitive industry, service providers are continuously undertaking initiatives to upgrade their existing service offerings This image provides information on recent expansions undertaken by various combination product service providers. To keep pace with the growing demand, many companies have undertaken expansion initiatives, such as establishing new facilities or expanding their existing capabilities, to strengthen their service portfolio This image provides list of Large Volume Wearable Injectors and Prefilled Syringes. Presently, over 210 combination products have been / are being developed for the treatment of various clinical conditions; these can be used for both parenteral as well as non-parenteral drug deliver

The key objective of drug device combination products market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for drug device combination products market during the forecast period. Our year-wise projections of the current and future opportunity within the combination product service providers market have further been segmented across types of devices (autoinjectors, prefilled syringes, large volume wearable injectors and other types of devices), service focus areas (particle testing, performance testing and product development), company size (very small, small, mid-sized, large and very large), and key geographical regions (North America, Europe, Asia and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

The opinions and insights presented in the market research report were also influenced by discussions held with senior stakeholders in the industry.

This image presents current market landscape of Large Volume Wearable Injector Combination Products. The pipeline features a variety of combination products that have been / are being developed for various therapeutic areas; majority of the products are being evaluated for the administration of biologics This image highlights the insightful outsourcing: go or no go framework analysis of Combination Products Developers. Built on our intellectual capital, we have proposed a proprietary framework to allow developers to decide whether to outsource manufacturing or keep it in-house; we expect majority of the small firms to outsource such operations This image provides information on the current and future market trends and potential growth of Combination Product Services Market. With the rising demand for combination products, the affiliated market for service providers is expected to grow at a steady annualized rate over the coming decade

Frequently Asked Questions

Question 1: What are drug device combination products?

Answer: In healthcare, a combination product entails multiple regulated components, including pharmaceutical entities and medical devices, which are chemically or physically combined to form a single unit.

Question 2: What is the drug device combination products market size for service providers?

Answer: The market size for service providers in the drug device combination products market is estimated to be worth $252 million in 2022.

Question 3: What is the projected market growth of services segment within the drug device combination products market?

Answer: The combination product services market is expected to grow at compounded annual growth rate (CAGR) of 10% during the forecast period 2022 - 2035.

Question 4: Who are the leading service providers in the drug device combination products market?

Answer: Examples of key service providers engaged in drug device combination products market (which have also been profiled in this market report; the complete list of companies is available in the full report) include EKG LABS, Eurofins Medical Device Testing, Exponent, Kymanox, Medical Engineering Technologies, Pace Analytical Services, Suttons Creek and West Pharmaceutical Services.

Question 5: How many companies presently claim to offer services for drug device combination products testing and development?

Answer: Presently, over 25 companies claim to offer services for drug device combination products testing and development globally.

Question 6: Which region is the hub for companies providing services for drug device combination products?

Answer: North America presently harbors the majority of the companies providing services for drug device combination products, with 29% of the companies being mid-sized in this region.

Question 7: Which type of service is primarily offered by companies engaged in the drug device combination products market?

Answer: Majority (75%) of the drug device combination products service providers offer process development and validation services for drug delivery systems / devices.

Question 8: What is an example of a drug device combination product?

Answer: Respimat inhaler is an example of a drug device combination product.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com